Eye Medication

Eye Medication Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 72 adverse event reports referencing Eye Medication, including 12 reports in which the animal died — a 1670.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Eye Medication. Reported administration routes include Ophthalmic, Unknown, Intraocular, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Eye Medication reports are Dog (58 reports), Cat (14 reports), with Dog accounting for the largest share. Within those species, Shih Tzu (9), Domestic Shorthair (7), Maltese (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Eye Medication are Lethargy (see also Central nervous system depression in 'Neurological') (17), Weight loss (11), Other abnormal test result NOS (9), Elevated serum alkaline phosphatase (SAP) (9). Of the 72 reports with a coded outcome, Ongoing is the leading category at 48.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Eye Medication.